These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 1373360)
1. Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Farinati F; De Maria N; Fornasiero A; Salvagnini M; Fagiuoli S; Chiaramonte M; Naccarato R Dig Dis Sci; 1992 May; 37(5):659-62. PubMed ID: 1373360 [TBL] [Abstract][Full Text] [Related]
2. Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. Farinati F; Salvagnini M; de Maria N; Fornasiero A; Chiaramonte M; Rossaro L; Naccarato R J Hepatol; 1990 Nov; 11(3):297-301. PubMed ID: 1705274 [TBL] [Abstract][Full Text] [Related]
3. [Regression of hepatocellular carcinoma under Tamoxifen: report of one case and review of the literature]. Macaigne G; Auriault ML; Boivin JF; Cheaib S; Chayette C; Deplus R Gastroenterol Clin Biol; 2002 Dec; 26(12):1165-7. PubMed ID: 12520204 [TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. Elba S; Giannuzzi V; Misciagna G; Manghisi OG Ital J Gastroenterol; 1994 Mar; 26(2):66-8. PubMed ID: 8032079 [TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. Pompili M; Rapaccini GL; Covino M; Pignataro G; Caturelli E; Siena DA; Villani MR; Cedrone A; Gasbarrini G Cancer; 2001 Jul; 92(1):126-35. PubMed ID: 11443618 [TBL] [Abstract][Full Text] [Related]
7. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. Riestra S; Rodriguez M; Delgado M; Suárez A; González N; de la Mata M; Diaz G; Miño-Fugarolas G; Rodrigo L J Clin Gastroenterol; 1998 Apr; 26(3):200-3. PubMed ID: 9600369 [TBL] [Abstract][Full Text] [Related]
8. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Manesis EK; Giannoulis G; Zoumboulis P; Vafiadou I; Hadziyannis SJ Hepatology; 1995 Jun; 21(6):1535-42. PubMed ID: 7768497 [TBL] [Abstract][Full Text] [Related]
9. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic factors in 105 Western patients. Lencioni R; Bartolozzi C; Caramella D; Paolicchi A; Carrai M; Maltinti G; Capria A; Tafi A; Conte PF; Bevilacqua G Cancer; 1995 Nov; 76(10):1737-46. PubMed ID: 8625042 [TBL] [Abstract][Full Text] [Related]
10. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). Doffoël M; Bonnetain F; Bouché O; Vetter D; Abergel A; Fratté S; Grangé JD; Stremsdoerfer N; Blanchi A; Bronowicki JP; Caroli-Bosc FX; Causse X; Masskouri F; Rougier P; Bedenne L; Eur J Cancer; 2008 Mar; 44(4):528-38. PubMed ID: 18242076 [TBL] [Abstract][Full Text] [Related]
12. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma. Cheng AL; Yeh KH; Fine RL; Chuang SE; Yang CH; Wang LH; Chen DS Hepatogastroenterology; 1998; 45(24):1955-60. PubMed ID: 9951847 [TBL] [Abstract][Full Text] [Related]
13. [The palliative treatment of hepatocarcinoma: chemoembolization vs. the combination of tamoxifen plus beta-interferon]. Maffei Faccioli A; Gerunda GE; Neri D; Zangrandi F; Merenda R; Bruttocao A; Meduri F; Barbazza F; Bisello M; Dimarzio E Chir Ital; 1994; 46(1):12-6. PubMed ID: 7517797 [TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Liu CL; Fan ST; Ng IO; Lo CM; Poon RT; Wong J Am J Gastroenterol; 2000 Jan; 95(1):218-22. PubMed ID: 10638587 [TBL] [Abstract][Full Text] [Related]
15. Oestradiol and testosterone blood levels in patients with viral cirrhosis and hepatocellular carcinoma. Pignata S; Daniele B; Galati MG; Esposito G; Vallone P; Fiore F; Ricchi P; Pergola M Eur J Gastroenterol Hepatol; 1997 Mar; 9(3):283-6. PubMed ID: 9096431 [TBL] [Abstract][Full Text] [Related]
16. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging. Gomaa AI; Al-Khatib A; Abdel-Razek W; Hashim MS; Waked I World J Gastroenterol; 2015 May; 21(18):5654-62. PubMed ID: 25987792 [TBL] [Abstract][Full Text] [Related]
17. Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review. Chou WC; Lee CL; Yang TS; Huang CY; Teng W; Tseng YT; Chen JS; Lin YC; Hou MM; Chang HH; Chia-Hsun Hsieh J J Formos Med Assoc; 2018 Feb; 117(2):153-163. PubMed ID: 28392193 [TBL] [Abstract][Full Text] [Related]
18. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Castells A; Bruix J; Brú C; Ayuso C; Roca M; Boix L; Vilana R; Rodés J Gastroenterology; 1995 Sep; 109(3):917-22. PubMed ID: 7657122 [TBL] [Abstract][Full Text] [Related]
19. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme). Lancet; 1998 Jul; 352(9121):17-20. PubMed ID: 9800740 [TBL] [Abstract][Full Text] [Related]
20. Controlled clinical trial of doxorubicin and tamoxifen versus tamoxifen monotherapy in hepatocellular carcinoma. Schachschal G; Lochs H; Plauth M Eur J Gastroenterol Hepatol; 2000 Mar; 12(3):281-4. PubMed ID: 10750647 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]